Glioblastoma Pipeline Landscape Report 2024: Pivotal Advances in Treatment Protocols and Drug Developments

58m ago, source:

The "Glioblastoma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The latest report on the Glioblastoma pipeline insights covers extensive research into the ...

Revolution Medicines: An Expensive Shot At A Massive Market Opportunity

14d ago, source:

Revolution is pioneering a unique precision-based approach to developing oncology drugs that target the RAS pathway. Read why ...

US FDA declines to approve Abeona’s skin disorder treatment

3d ago, source: WSAY

Abeona Therapeutics said on Monday the U.S. health regulator had declined to approve its treatment for a rare skin blistering ...

Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight

7d ago, source:

DelveInsight's Radioimmunoassay Market Insights report provides the current and forecast market analysis, individual leading ...

FDA rejects Abeona cell therapy, asks for more manufacturing data

2d ago, source: BioPharma Dive

The complete response letter for Abeona’s treatment is one of several manufacturing setbacks for cell and gene therapy developers in recent years.

Allogene Therapeutics Announces Q2 Investor Conference Participation

16d ago, source: TMCnet

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the ...

Abeona Therapeutics Shares Down 53% After FDA Complete Response Letter

3d ago, source:

By Josh Beckerman Abeona Therapeutics shares fell 53%, to $3.45, after hours as its application for pz-cel received a Complete Response Letter from the ...

Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting

1d ago, source:

Iovance will host an event on the evening of Friday, May 31, 2024 to summarize the data highlights at ASCO. The live and archived event webcast will be available in the Investors section of the ...

Cullinan Oncology Shares Jump 21% on Planned Autoimmune Diseases Expansion, Private Placement

9d ago, source:

By Sabela Ojea Shares of Cullinan Oncology on Tuesday jumped after the company said it is expanding its focus toward autoimmune diseases. Shares rose 21% ...

DelveInsight Business Research, LLP: Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight

7d ago, source:

The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics ...